JP2023531517A5 - - Google Patents
Info
- Publication number
- JP2023531517A5 JP2023531517A5 JP2022579725A JP2022579725A JP2023531517A5 JP 2023531517 A5 JP2023531517 A5 JP 2023531517A5 JP 2022579725 A JP2022579725 A JP 2022579725A JP 2022579725 A JP2022579725 A JP 2022579725A JP 2023531517 A5 JP2023531517 A5 JP 2023531517A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026000046A JP2026042854A (ja) | 2020-06-24 | 2026-01-04 | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043641P | 2020-06-24 | 2020-06-24 | |
| US63/043,641 | 2020-06-24 | ||
| PCT/US2021/038661 WO2021262836A1 (en) | 2020-06-24 | 2021-06-23 | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026000046A Division JP2026042854A (ja) | 2020-06-24 | 2026-01-04 | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531517A JP2023531517A (ja) | 2023-07-24 |
| JP2023531517A5 true JP2023531517A5 (https=) | 2024-07-01 |
Family
ID=77265178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579725A Pending JP2023531517A (ja) | 2020-06-24 | 2021-06-23 | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
| JP2026000046A Pending JP2026042854A (ja) | 2020-06-24 | 2026-01-04 | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026000046A Pending JP2026042854A (ja) | 2020-06-24 | 2026-01-04 | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230250129A1 (https=) |
| EP (1) | EP4172171A1 (https=) |
| JP (2) | JP2023531517A (https=) |
| CN (1) | CN115768781A (https=) |
| AR (1) | AR122733A1 (https=) |
| AU (1) | AU2021296846A1 (https=) |
| CA (1) | CA3183248A1 (https=) |
| IL (1) | IL299176A (https=) |
| MX (3) | MX2022016343A (https=) |
| TW (1) | TW202233198A (https=) |
| WO (1) | WO2021262836A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| EP4321519B1 (en) | 2018-10-12 | 2026-04-08 | Sage Therapeutics, LLC | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| KR20250174100A (ko) | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| EP4711377A1 (en) * | 2023-05-11 | 2026-03-18 | Shujing Biopharma Co., Ltd | Steroid compound, preparation method therefor, and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| MA45599A (fr) * | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| MX2020006599A (es) * | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| EP3750909B1 (en) * | 2018-02-11 | 2025-03-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| WO2020132504A1 (en) * | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
-
2021
- 2021-06-23 US US18/003,215 patent/US20230250129A1/en active Pending
- 2021-06-23 EP EP21752283.8A patent/EP4172171A1/en active Pending
- 2021-06-23 CN CN202180044419.5A patent/CN115768781A/zh active Pending
- 2021-06-23 CA CA3183248A patent/CA3183248A1/en active Pending
- 2021-06-23 WO PCT/US2021/038661 patent/WO2021262836A1/en not_active Ceased
- 2021-06-23 AU AU2021296846A patent/AU2021296846A1/en active Pending
- 2021-06-23 IL IL299176A patent/IL299176A/en unknown
- 2021-06-23 JP JP2022579725A patent/JP2023531517A/ja active Pending
- 2021-06-23 MX MX2022016343A patent/MX2022016343A/es unknown
- 2021-06-24 TW TW110123100A patent/TW202233198A/zh unknown
- 2021-06-24 AR ARP210101745A patent/AR122733A1/es unknown
-
2022
- 2022-12-15 MX MX2024008998A patent/MX2024008998A/es unknown
- 2022-12-15 MX MX2024008999A patent/MX2024008999A/es unknown
-
2026
- 2026-01-04 JP JP2026000046A patent/JP2026042854A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023531517A5 (https=) | ||
| JP2022534424A5 (https=) | ||
| JP2022510683A5 (https=) | ||
| JP2020526561A5 (https=) | ||
| JP2021502387A5 (https=) | ||
| RU2405774C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| JP2022504607A5 (https=) | ||
| JP2021510695A5 (https=) | ||
| JPWO2020017587A5 (https=) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2009532464A5 (https=) | ||
| RU2015115400A (ru) | Гетероароматические соединения и их применение в качестве допаминовых D1 лигантов | |
| JP2022514385A5 (https=) | ||
| JP2015515976A5 (https=) | ||
| JP2024524766A5 (https=) | ||
| JP2018515525A5 (https=) | ||
| JP2010504346A5 (https=) | ||
| JP2023508097A5 (https=) | ||
| JP2014531449A5 (https=) | ||
| CA2737999A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma | |
| JP2018522861A5 (https=) | ||
| RU2018104868A (ru) | 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 | |
| JP2007502295A5 (https=) | ||
| JP2015514679A5 (https=) | ||
| JP2017525744A5 (https=) |